GLP-1s and Heart Health

The SELECT trial showed that semaglutide reduced the risk of major cardiovascular events — heart attack, stroke, and cardiovascular death — in adults with overweight or obesity and established cardiovascular disease, who did not have type 2 diabetes. This was a landmark finding. Here's what it means — and why nutrition still plays a role.

What did the SELECT trial show?

The SELECT trial was a large, randomised, placebo-controlled cardiovascular outcomes trial. It enrolled adults with a BMI of 27 or above and established cardiovascular disease — meaning they had a prior heart attack, stroke, or peripheral arterial disease — and crucially, they did not have type 2 diabetes.

The trial showed that treatment with semaglutide (Wegovy) led to a meaningful reduction in the rate of major adverse cardiovascular events (MACE) — a composite of heart attack, stroke, and cardiovascular death — compared to placebo.

This finding was significant for several reasons: it demonstrated cardiovascular benefit independent of blood sugar control (since participants didn't have diabetes), and it supported a specific FDA approval for reducing cardiovascular risk in this population.

Who was the SELECT trial for?

The SELECT trial population was specific:

• Adults with overweight or obesity (BMI ≥ 27)
• With established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease)
• Who did not have type 2 diabetes

This distinction matters. The SELECT finding does not straightforwardly extend to people without established CVD, or to people who have cardiovascular disease alongside type 2 diabetes (where different trials apply). The specific population enrolled determines who the evidence applies to.

Why do omega-3 and magnesium matter during rapid weight loss?

Even when you're on a GLP-1, nutrition still matters for cardiovascular health — perhaps more so, because significant weight loss changes the body's cardiovascular risk landscape and eating much less creates real nutritional gaps.

Omega-3 (EPA+DHA) has some of the strongest and most consistent human trial evidence for heart and metabolic support of any nutritional supplement. During rapid weight loss on a GLP-1, food volume drops significantly — including oily fish and other omega-3 sources. An EPA+DHA supplement covers this gap at a time when cardiovascular risk markers are actively shifting.

Magnesium is involved in heart rhythm regulation, blood pressure, and vascular function. It's also the first micronutrient to fall when you eat significantly less. Low magnesium is associated with increased cardiovascular risk in observational research — and eating very little reliably depletes dietary magnesium intake. Magnesium glycinate or malate are well-absorbed forms with minimal GI side effects.

These are nutritional support measures, not treatments for cardiovascular disease. They address real gaps created by eating much less — they don't replace prescribed cardiovascular medications or clinical care.

What this doesn't mean

The SELECT trial result is important but should not be over-interpreted:

• It does not mean semaglutide is a heart drug for the general population
• It does not mean weight loss alone explains the full cardiovascular benefit
• It does not apply to people without established cardiovascular disease
• It does not allow you to stop heart medications — GLP-1s and cardiology medications address different mechanisms and should be managed by your clinical team together

If you have established cardiovascular disease and are considering or already on a GLP-1, your cardiologist and prescribing clinician should know. This is a conversation for your clinical team, not a decision to make alone.

Frequently asked questions

Does this mean semaglutide is a heart medication?
It means semaglutide has demonstrated cardiovascular benefit in a specific population in a clinical trial (SELECT), leading to an FDA approval for reducing CV risk in adults with obesity and established CVD. It is not a standalone heart medication — speak to your cardiologist and prescriber.

I'm on semaglutide for weight loss without cardiovascular disease — is my heart protected?
The SELECT trial enrolled people with established cardiovascular disease. The findings don't directly extrapolate to people without CV disease. The primary purpose of your prescription should guide the conversation with your clinician.

Why do omega-3 and magnesium matter when on a GLP-1?
Rapid weight loss and significantly reduced food intake affect cardiovascular risk markers and electrolyte balance. Omega-3 (EPA+DHA) has strong, consistent human trial evidence for heart and metabolic support. Magnesium is involved in heart rhythm regulation and blood pressure. Eating much less often creates gaps in both.

Can I stop my heart medications if I start a GLP-1?
Never stop or adjust prescribed heart medications without guidance from your cardiologist or prescribing clinician. GLP-1s and heart medications address different aspects of cardiovascular health.